Danaher to Present at J.P. Morgan Healthcare Conference

Wed Jan 2, 2013 4:01pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130102:nHUGcRPb


Washington, D.C., January 2, 2013 - Danaher Corporation (NYSE:DHR) announced that President and
Chief Executive Officer, H. Lawrence Culp, Jr. will be presenting at the J.P. Morgan Healthcare
Conference in San Francisco, CA on Wednesday, January 9, 2013 at 3:00 p.m. PST. The audio will be
simultaneously webcast on www.danaher.com. A replay of the webcast will be available for one week
following the presentation.

* * *

Danaher is a science and technology leader that designs, manufactures, and markets innovative
products and services to professional, medical, industrial, and commercial customers.  Our premier
brands are among the most highly recognized in each of the markets we serve.  The Danaher Business
System provides a foundation to our 59,000 associates around the world, serving customers in more
than 125 countries.  In 2011, we generated $16.1 billion of revenue.  For more information please
visit our website: www.danaher.com http://www.danaher.com/ .

Please contact:

Matt R. McGrew
Vice President, Investor Relations
Danaher Corporation
2200 Pennsylvania Avenue, N.W., Suite 800W
 Washington, D.C. 20037
Telephone: (202) 828-0850
Fax: (202) 828-0860


---------------------------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Danaher Corporation via Thomson Reuters ONE


HUG#1667858

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.